NCT01424397View on ClinicalTrials.gov

Intranasal SB-705498 in Allergic Rhinitis (AR) Patients

PHASE2CompletedINTERVENTIONAL

Enrollment

70

Participants

Timeline

Start Date

April 14, 2011

Primary Completion Date

July 7, 2011

Study Completion Date

July 7, 2011

Conditions

Rhinitis

Interventions

DRUG

SB-705498

12mg intranasal

DRUG

FP

200ug intranasal

DRUG

placebo

placebo intranasal

Trial Locations (1)

A-1150

GSK Investigational Site, Vienna

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY

NCT01424397 - Intranasal SB-705498 in Allergic Rhinitis (AR) Patients | Biotech Hunter | Biotech Hunter